TX-FLUENCE
2.9.2021 14:02:06 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, and HortiPolaris, a Beijing, China-based greenhouse producing 20 varieties of tomatoes and eight types of lettuce, announced the implementation of Fluence LED lighting solutions into HortiPolaris’s cultivation and research facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005266/en/
HortiPolaris is a science and technology leader in the region, standing on the cutting edge of farming and education in booming Beijing where the population and demand for fresh, quality produce continues to grow. Its state-of-the-art greenhouse—inspired by the founder’s work in the Netherlands—represents the future of controlled environment agriculture, housing 2,000 square meters of lettuce and 22,850 square meters of tomatoes. HortiPolaris originally equipped its farm with HPS lighting, but found energy costs were too high for a market that valued quality over yield, prompting the company to switch to LED lighting systems that provide crop consistency, energy efficiency and seasonal cultivation flexibility for growers.
“We can use LEDs not only in the winter period, but also in the spring, autumn and even summer to increase yield and stabilize quality,” said Dan Xu, founder and general manager of HortiPolaris. “We are carrying out trials together with Fluence to figure out the best combination of light intensity and light spectrum in order to increase the neutral level to maximize margin and to differentiate ourselves in the market.”
HortiPolaris distributes a variety of popular tomato and lettuce cultivars to local and regional markets and leverages Fluence’s broad-spectrum VYPR LED lighting solutions in its greenhouse and Fluence’s RAZR LED solutions in HortiPolaris’s vertical propagation racks.
“Transitioning from HPS lighting to Fluence LED solutions affords growers a way to improve the quality of their produce such as color and consistency—critical factors shoppers in the growing Beijing region are prioritizing,” said David Cohen, CEO of Fluence. “We are proud to partner with HortiPolaris, an innovator and evolved horticulture leader in the rapidly expanding Chinese market, that recognizes the advantages of LED technology developmentally for crops’ growing cycles and also operationally in facility design.”
Applying Fluence’s LED lighting solutions provides growers better control over plants’ external variables such as temperature and humidity, eliminating once-crucial concerns about overheating as a result of growing under HPS lighting.
“There are several advantages to Fluence lighting solutions,” said Yuchong Chen, technical assistant at HortiPolaris. “Not only can they provide maximum light intensity, but they also allow us to control intensity for different growing stages. Additionally, the uniform light the RAZR fixtures provide is quite important for grafting. That’s why we use Fluence LED lighting solutions in all seasons to increase yield and stabilize the quality of our grow.”
Fluence’s partnership with HortiPolaris bolsters the farm’s ability to harvest quality produce and supply the market year-round. The companies’ ongoing trials to discover optimum lighting strategies for unique cultivation environments are charting the course for the future of innovative food production that will ultimately help the world grow smarter.
To learn more about Fluence, its customers and the company’s ongoing research, visit www.fluence.science/case-studies .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom